Oral Glibenclamide in Preterm Infants With Hyperglycaemia (GALOP)

Phase 2 Active not recruiting 35 enrolled Assistance Publique - Hôpitaux de Paris URC-CIC Paris Descartes Necker Cochin · collab

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to confirm hypothesis that Glibenclamide can be administered orally and is an alternative to insulin therapy in treating transient hyperglycemia of premature newborns.

Timeline

Start: 2023-05-20
Primary completion: 2025-10-30
Completion: 2026-04-30

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Glyburide	Small molecule	6 mg/ml	Other

Indications

No indication recorded.